Provectus Biopharmaceuticals (STU:PXY) Cyclically Adjusted PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PXY Provectus Biopharmaceuticals Inc STU:PXY
35 GF Score
Price €0.05
! 3 Warning Signs
View Full Analysis

What is Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Provectus Biopharmaceuticals  (STU:PXY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.85 7.88 15.99 0.00 0.00

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:PXY vs PSTV, ALGS, ATNM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:PXY
35GF Score
Provectus Biopharmaceuticals Inc STU:PXY
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Provectus Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Provectus Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.014/330.2130*330.2130
=-0.014

Current CPI (Mar. 2026) = 330.2130.

Provectus Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.038 241.018 0.052
201609 0.019 241.428 0.026
201612 0.009 241.432 0.012
201703 -0.002 243.801 -0.003
201706 -0.010 244.955 -0.013
201709 -0.017 246.819 -0.023
201712 -0.023 246.524 -0.031
201803 -0.027 249.554 -0.036
201806 -0.031 251.989 -0.041
201809 -0.034 252.439 -0.044
201812 -0.040 251.233 -0.053
201903 -0.043 254.202 -0.056
201906 -0.048 256.143 -0.062
201909 -0.053 256.759 -0.068
201912 -0.056 256.974 -0.072
202003 -0.060 258.115 -0.077
202006 -0.062 257.797 -0.079
202009 -0.061 260.280 -0.077
202012 -0.062 260.474 -0.079
202103 -0.066 264.877 -0.082
202106 -0.005 271.696 -0.006
202109 -0.006 274.310 -0.007
202112 -0.009 278.802 -0.011
202203 -0.011 287.504 -0.013
202206 -0.014 296.311 -0.016
202209 -0.017 296.808 -0.019
202212 -0.014 296.797 -0.016
202303 -0.016 301.836 -0.018
202306 -0.016 305.109 -0.017
202309 -0.017 307.789 -0.018
202312 -0.017 306.746 -0.018
202403 -0.016 312.332 -0.017
202406 -0.017 314.175 -0.018
202409 -0.012 315.301 -0.013
202412 -0.014 315.605 -0.015
202503 -0.011 319.799 -0.011
202506 -0.012 322.561 -0.012
202509 -0.013 324.800 -0.013
202512 -0.013 324.054 -0.013
202603 -0.014 330.213 -0.014

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Provectus Biopharmaceuticals Business Description

Other Exchanges PVCT:USA
Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score

Get the complete analysis for STU:PXY

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price